Corcept Therapeutics Posts Q3 EPS of $1.01
Q3 EPS was $1.01, versus the FactSet estimate of $0.79.
Related stories
Jackson Financial Q3 Adjusted EPS $7.55
M impact | EARNINGS | Nov 03, 2026, 10:35 PM UTC
BlueLinx Reports 8.5% Sales Growth, Q4 Volumes Expected Lower
BlueLinx reported third-quarter 2026 sales up 8.5% year over year and gross margin of 16.1%. It posted a small GAAP net loss while adjusted EBITDA grew 42% versus the prior period.
M impact | EARNINGS | Nov 03, 2026, 10:33 PM UTC
AMD Guides to Fourth-Quarter 2026 Revenue of $16.49B–$17.51B
AMD expects revenue of $16.49 billion to $17.51 billion in the fourth quarter of 2026, alongside its third-quarter results.
M impact | EARNINGS | Nov 03, 2026, 10:33 PM UTC
Suncor Energy Reports Q3 Adjusted FFO of C$5.75 per Share
M impact | EARNINGS | Nov 03, 2026, 10:33 PM UTC
Boardwalk REIT Reports Q3 Adjusted FFO of C$1.04 Per Share
L impact | EARNINGS | Nov 03, 2026, 10:32 PM UTC
Charter Hall Long WALE REIT Reaffirms FY27 Guidance at 25.5 Cents
The REIT reaffirmed FY27 operating earnings and distributions guidance of 25.5 cents per security each.
M impact | EARNINGS | Nov 03, 2026, 10:32 PM UTC